Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

Go back to Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
(NASDAQ: ROIV) Delayed: 38.99 --0 (-0%)
Previous Close $38.99    52 Week High
Open $38.99    52 Week Low
Day High $38.99    P/E N/A 
Day Low $38.99    EPS
Volume 3,069       

(NASDAQ: ROIVW) Delayed: 2.75 --0 (-0%)
Previous Close $2.75    52 Week High
Open $25.55    52 Week Low
Day High $2.75    P/E N/A 
Day Low $2.75    EPS
Volume 555